Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
78.1(c) 79.9(c) 80(c) 80.85(c) 82.5 Last
126 860 80 249 158 169 231 024 61 597 Volume
-1.08% +2.30% +0.13% +1.06% +2.04% Change
More quotes
Financials
Sales 2020 2 654 M 3 173 M 3 173 M
Net income 2020 461 M 552 M 552 M
Net Debt 2020 717 M 857 M 857 M
P/E ratio 2020 14,6x
Yield 2020 1,27%
Sales 2021 2 811 M 3 361 M 3 361 M
Net income 2021 529 M 633 M 633 M
Net Debt 2021 237 M 284 M 284 M
P/E ratio 2021 12,6x
Yield 2021 1,29%
Capitalization 6 678 M 7 982 M 7 984 M
EV / Sales 2020 2,79x
EV / Sales 2021 2,46x
Nbr of Employees 5 807
Free-Float 42,0%
More Financials
Company
Ipsen specializes in the research, development, manufacturing and marketing of medications. Sales break down by family of products as follows: - specialty drugs (89.3%). Sales break down by therapeutic area between oncology (80.2%), neuroscience (17%) and rare diseases (2.8%); - consumer healthcare products (10.7%): products used in the treatment of gastrointestinal disorders, neurodegenerative pathologies and... 
Sector
Pharmaceuticals
Calendar
12/01Capital Markets Day
More about the company
Notations Surperformance© of Ipsen
Trading Rating : Investor Rating :
More Ratings
All news about IPSEN
02:13aIPSEN : expects to generate over $3 billion by 2024 for drug pipeline expansion
RE
01:07aIPSEN : new strategic priorities unveiled at virtual Capital Markets Day event
PU
01:01aIPSEN : Highlights New Strategic Priorities and Provides Mid-Term Financial Outl..
BU
11/30IPSEN : receives FDA Fast Track designation for investigational irinotecan lipos..
PU
11/25EACD 2020 : How the use of functional assessments in clinical trials provides me..
PU
11/18ALERT : New purchases in the Investor Europe portfolio
10/27IPSEN : Disclosure of Transactions in Own Shares Between 10/19/2020 And 10/20/20..
BU
10/23IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
AQ
10/22IPSEN : Q3 2020 Sales Conference Call – Thursday, October 22, 2020
PU
10/22IPSEN : announces sales growth over the first 9 months of 2020
PU
10/22IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
PU
10/22IPSEN : Delivers Sales Growth in the First Nine Months of 2020 Despite the Impac..
BU
10/22IPSEN : 3rd quarter results
CO
10/20IPSEN : Disclosure of Transactions in Own Shares between 10/12/2020 and 10/16/20..
BU
10/16IPSEN : Q3 2020 Sales Conference Call – Thursday, October 22, 2020
PU
More news
News in other languages on IPSEN
03:40aIPSEN : veut porter sa capacité d'investissement à ?3 mds d'ici 2024
03:11aLes valeurs à suivre aujourd'hui à la Bourse de Paris Mardi 1er décembre 202..
02:50aSTOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
02:45aIPSEN : croissance annuelle des ventes prévue entre 2% et 5%
02:16aIPSEN : A suivre aujourd'hui
More news
Analyst Recommendations on IPSEN
More recommendations
Stock Trading Strategies
IPSEN - 11/02
Attractive timing to go long again
BUY
More Stock Trading Analysis
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 96,49 €
Last Close Price 80,85 €
Spread / Highest target 39,8%
Spread / Average Target 19,3%
Spread / Lowest Target 0,19%
EPS Revisions
Managers
NameTitle
David G. Loew Chief Executive Officer & Director
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN2.34%7 982
JOHNSON & JOHNSON-0.82%379 086
ROCHE HOLDING AG-3.66%285 972
PFIZER, INC.3.21%206 939
NOVARTIS AG-11.80%203 829
MERCK & CO., INC.-12.19%202 049